The invention relates to oleoyl-lysophosphatidylinositol (oleoyl-LPI) and new synthetic derivatives thereof and uses thereof, and to pharmaceutical compositions comprising such compounds. The invention provides activators and/or up-regulators of glucoregulatory hormones such as glucagon like peptide-1 (GLP-1), and more specifically to agonists, partial agonists and reverse antagonists of GPR119 or activatiors of GLP-1 activity and/or synthesis and/or secretion, and pharmaceutical compositions comprising same, uses thereof in therapy of diabetes, obesity and other metabolic disorders.
本发明涉及油酰-赖
氨酸
磷脂酰肌醇(油酰-L
PI)及其新的合成衍
生物,以及它们的用途,以及包含这些化合物的制药组合物。本发明提供了
胰高血糖素样肽-1(GLP-1)等糖调节激素的激活剂和/或上调剂,更具体地是GPR119的激动剂,部分激动剂和反向拮抗剂或GLP-1活性和/或合成和/或分泌的激活剂,以及包含它们的制药组合物,将其用于治疗糖尿病、肥胖症和其他代谢性疾病。